CH50 Assay – Half Hemolytic Complement Activity Assessment: Principles, Methods, and Applications

Half hemolytic activity assessment (CH50 assay) is a functional bioassay that quantifies the total lytic capacity of the complement system by determining the serum dilution that lyses 50% of antibody-sensitized erythrocytes. As a key endpoint in immunotoxicity studies, biological product characterization, and clinical immunology, CH50 testing is widely performed by accredited third-party laboratories to support pharmaceutical development, medical device blood-compatibility evaluation, and regulatory submissions. This article explains the scientific principles, sample requirements, test items, methodologies, and typical applications of 50% hemolysis activity assessment.

Technical Overview

The complement system comprises more than thirty soluble and membrane-bound proteins that act through the classical, lectin, and alternative pathways to mediate opsonization, inflammation, and complement-dependent cytotoxicity. The half hemolytic activity assay, universally known as the CH50 (50% hemolytic complement) test, is the reference functional method for evaluating the global activity of the classical pathway in serum or other biological fluids.

In the CH50 assay, a standardized suspension of sheep erythrocytes is sensitized with a specific rabbit anti-sheep erythrocyte antiserum (hemolysin, historically termed amboceptor). When serially diluted serum is added, complement components assemble on the antibody-coated cell surface, form the membrane attack complex, and lyse the cells. The CH50 value is defined as the reciprocal of the highest serum dilution that produces 50% lysis of the sensitized erythrocyte suspension, and it is reported in hemolytic units per milliliter (U/mL).

The choice of the 50% endpoint is grounded in complement biochemistry. The relationship between serum concentration and hemolysis follows a sigmoidal dose-response curve described by the von Krogh equation; the steepest, most linear portion of this curve lies at the 50% lysis point, where analytical sensitivity is maximal and small changes in complement concentration produce the largest measurable change in hemolysis.

Because lysis of sensitized erythrocytes requires every classical pathway component, from C1q through C4, C2, C3, C5, and the terminal C5b-9 complex, to be present and functionally active, CH50 serves as a highly efficient integrity screen. A single significant component deficiency typically reduces the result to near zero. The complementary AH50 assay, which evaluates the alternative pathway using unsensitized rabbit erythrocytes, is frequently run in parallel to localize pathway-specific defects.

Testing Samples

Human Serum

Peripheral blood is collected into plain tubes, allowed to clot at room temperature, and centrifuged to obtain serum. Because complement proteins are thermolabile and are consumed during clotting to a limited extent, standardized handling is essential: samples should be separated promptly, kept cold, and frozen at −70°C or below if not analyzed immediately.

Animal Serum from Preclinical Studies

Serum from rats, mice, rabbits, guinea pigs, beagle dogs, and non-human primates collected in toxicology and immunotoxicity studies is routinely analyzed to assess complement status. Assay conditions, erythrocyte selection, and calibration ranges must be adapted to the species under investigation.

Plasma-Derived and Biological Products

Immunoglobulin preparations, serum-containing culture media, and other plasma-derived biologicals may be tested to document residual or inadvertent complement activity as part of product characterization and batch release support.

Test Article Extracts for Medical Devices

In blood-compatibility evaluation aligned with ISO 10993-4 and GB/T 16886.4, extracts of blood-contacting materials can be incubated with complement-preserved human serum, and the residual CH50 activity is measured to quantify complement consumption mediated by the material.

Testing Items

Typical study designs offered by accredited third-party laboratories include the following measurable items:

• Total classical pathway complement activity (CH50, expressed in U/mL).
• Alternative pathway activity (AH50) using unsensitized rabbit erythrocytes in magnesium-EGTA buffer.
• Complete dose-response hemolysis profiles, reported as percent lysis at each serial serum dilution.
• Complement consumption or inhibition studies, expressed as residual CH50 after incubation of serum with a test article, material extract, or drug candidate.
• Method suitability controls, including 0% and 100% hemolysis controls, cell and serum blanks, and calibration against an assigned reference serum.

Final reports generally present the calculated CH50 value, the interpolated dose-response curve, the analytical reference interval, and a scientific interpretation of whether the observed activity falls within normal, elevated, or deficient ranges for the relevant species.

Testing Methods

Classical Spectrophotometric CH50 Assay

The conventional tube-based method proceeds through several controlled steps. A 2-5% sheep erythrocyte suspension is standardized photometrically and sensitized with a sub-agglutinating concentration of hemolysin. Serial two-fold dilutions of test serum are prepared in gelatin veronal-buffered saline containing calcium and magnesium ions, mixed with the sensitized cells, and incubated at 37°C for 30 to 60 minutes. After centrifugation, hemoglobin release in the supernatant is quantified by absorbance at 540-541 nm. Percent lysis at each dilution is normalized against water-lysed (100%) and buffer-only (0%) controls, the data are linearized using the von Krogh log-log transformation, and the 50% endpoint dilution is interpolated to calculate the CH50 value.

Plate-Based and Automated Liposome Assays

High-throughput microplate adaptations reduce sample volume and improve reproducibility. Liposome-based automated methods employ antigen-loaded liposomes encapsulating an enzyme substrate; antibody-mediated complement activation lyses the liposomes, releasing the marker, and the enzymatic product is quantified photometrically. These platforms are well suited to large preclinical studies and serial pharmacodynamic monitoring.

Alternative Pathway AH50 Assay

AH50 testing uses rabbit erythrocytes, which spontaneously activate the human alternative pathway, suspended in buffer containing magnesium and EGTA to chelate calcium and thereby block the classical and lectin pathways. Combined interpretation of CH50 and AH50 results allows precise localization of pathway defects.

Quality Control and Data Acceptance

Assays are calibrated against reference sera with assigned potency, and each run includes controls spanning the measuring range. Replicate precision is typically required to fall within 10-15% coefficient of variation, and sample integrity is documented through chain-of-custody and freeze-thaw records. Where the study is performed in a medical device or material context, method alignment with ISO 10993-4, GB/T 16886.4, and ASTM F756 principles is recommended, with Good Laboratory Practice documentation to support regulatory review.

Applications

Half hemolytic activity assessment supports decision-making across clinical, industrial, and research settings:

• Clinical immunology: screening for hereditary complement component deficiencies and monitoring acquired hypocomplementemia in systemic lupus erythematosus, immune-complex disease, cryoglobulinemia, severe hepatic failure, and sepsis.
• Pharmaceutical development: characterizing complement-modulating therapeutics, selecting pharmacodynamic doses of complement inhibitors, and investigating complement activation-related pseudoallergy associated with biologics and nanomedicines.
• Medical device evaluation: documenting complement compatibility of blood-contacting devices and materials under ISO 10993-4 and GB/T 16886.4 blood-interaction test strategies.
• Vaccine and adjuvant research: assessing the complement-activating properties of formulations and delivery systems.
• Biopharmaceutical quality control: verifying residual complement activity or complement consumption capacity of plasma-derived products.
• Preclinical safety assessment: incorporating functional complement endpoints into immunotoxicity study panels alongside hematology and immunophenotyping data.

The same photometric platform can be extended to concentration-response hemolysis testing (HC50 determination) for compounds or surfactant-like test articles with direct erythrocyte-membrane activity, distinguishing membrane disruption from complement-mediated lysis.

FAQ

What does a CH50 result actually represent?

The CH50 value represents the functional, integrated activity of the complete classical complement pathway, not the concentration of any single protein. It answers the question of whether the whole lytic cascade, from antibody recognition through membrane attack complex formation, can execute normally.

Why is the 50% lysis point used instead of complete hemolysis?

The hemolysis-versus-complement curve is sigmoidal, and its steepest slope occurs at 50% lysis. Measuring at this midpoint maximizes analytical sensitivity and minimizes error, whereas complete lysis endpoints sit on a flat plateau where large changes in activity produce negligible changes in absorbance.

Which sample type is acceptable for CH50 testing?

Serum is the preferred matrix. EDTA plasma is unsuitable for functional CH50 testing because chelation of calcium and magnesium inactivates the classical pathway. Samples should be frozen at −70°C or below and protected from repeated freeze-thaw cycles.

What causes a decreased CH50 value?

Decreased activity may reflect hereditary deficiency of a classical pathway component, ongoing complement consumption in immune-complex diseases such as lupus, cryoglobulinemia, severe infection or sepsis, advanced liver disease with impaired synthesis, or complement inhibition by a therapeutic or test article under investigation.

How do CH50 and AH50 results differ in interpretation?

A low CH50 with a normal AH50 points to a defect in the early classical components such as C1, C4, or C2; a low AH50 with a normal CH50 suggests an alternative pathway defect; and concordantly low values typically indicate deficiency or consumption of C3 or shared terminal components C5 through C9.

What interferences should be avoided during sampling?

Grossly hemolyzed samples interfere with the photometric readout, lipemia can distort absorbance, and delayed processing at room temperature degrades complement activity. Strict pre-analytical control, including rapid serum separation and low-temperature storage, is essential for valid results.